Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - A systematic review and meta-analysis

British Journal of Clinical Pharmacology

Volumn 79, Issue 5, 2015, Pages 733-743

  Hirst, Jennifer A ^a,b   Farmer, Andrew J ^a,b   Feakins, Benjamin G ^a,b   Aronson, Jeffrey K ^a,b   Stevens, Richard J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b University of Manchester   (United Kingdom)

Author keywords

beta blockers; diabetes; diuretics; glycaemic control; meta analysis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; THIAZIDE DIURETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SYSTEMATIC REVIEW; ANALYSIS; BLOOD; BLOOD PRESSURE; COMPLICATION; DRUG EFFECTS; HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENERGIC BETA-ANTAGONISTS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS; DIURETICS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84928330927     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12543     Document Type: Article

References (58)

1. Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME,. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr 2013; 5: 57.
2. Luijks H, Schermer T, Bor H, van Weel C, Lagro-Janssen T, Biermans M, de Grauw W,. Prevalence and incidence density rates of chronic comorbidity in type 2 diabetes patients: an exploratory cohort study. BMC Med 2012; 10: 128.
3. Novo Nordisk A/S. Annex 1. Summary of product characteristics. Section 4.5 Interaction with other medicinal products and other forms of interaction. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000441/WC500033307.pdf (last accessed 27 November 2014).
4. Diabetes-in-Control. Drugs that can affect blood glucose levels. 2011. Available at http://www.diabetesincontrol.com/images/tools/druglistaffectingbloodglucose.pdf (last accessed 27 November 2014).
5. dLife. Drugs that affect blood glucose. Available at http://www.dlife.com/diabetes/type-2/diabetes-treatment/drugs-that-raise-blood-glucose (last accessed 27 November 2014).
6. Chan JC, Cockram CS, Critchley JA,. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996; 15: 135-157.
7. Popp DA, Shah SD, Cryer PE,. Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus. J Clin Invest 1982; 69: 315-326.
8. Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP,. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 2013; 168: 3572-3579.
9. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Park S,. Acute hyperglycemia and activation of the beta-adrenergic system exhibit synergistic inhibitory actions on growth hormone (GH) releasing hormone-induced GH release. Eur J Endocrinol 2003; 148: 635-640.
10. Hussain T, Greenhalgh K, McLeod KA,. Hypoglycaemic syncope in children secondary to beta-blockers. Arch Dis Child 2009; 94: 968-969.
11. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS,. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236.
12. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F,. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126: 955-959.
13. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ,. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996; 14: 489-494.
14. Balamuthusamy S, Molnar J, Adigopula S, Arora R,. Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: a systematic review and meta-analysis. Am J Ther 2009; 16: 133-142.
15. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J,. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886-1892.
16. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR,. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29-35.
17. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN,. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993; 118: 529-539.
18. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J,. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166: 2191-2201.
19. Warram JH, Laffel LM, Valsania P, Christlieb AR, Krolewski AS,. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991; 151: 1350-1356.
20. Sander GE, Giles TD,. Thiazide diuretics and beta-blockers in the treatment of hypertension in diabetes mellitus. J Clin Hypertens (Greenwich) 2011; 13: 296-300.
21. Shafi T, Appel LJ, Miller ER 3rd, Klag MJ, Parekh RS,. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008; 52: 1022-1029.
22. Higgins JPT, Green S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available at http://www.cochrane-handbook.org (last accessed 27 November 2014).
23. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD,. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-2650.
24. Mason RP, Giles TD, Sowers JR,. Evolving mechanisms of action of beta blockers: focus on nebivolol. J Cardiovasc Pharmacol 2009; 54: 123-128.
25. Smith C, Teitler M,. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther 1999; 13: 123-126.
26. Dornhorst A, Powell SH, Pensky J,. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. Lancet 1985; 1: 123-126.
27. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR, BEST Investigators. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003; 42: 914-922.
28. Gundersen T, Kjekshus J,. Timolol-related reduction in mortality and reinfarction in diabetic patients surviving acute myocardial infarction. Horm Metab Res Suppl 1985; 15: 58-60.
29. Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM,. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995; 38: 853-859.
30. Janka HU, Ziegler AG, Disselhoff G, Mehnert H,. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S96-99.
31. Malmberg K, Herlitz J, Hjalmarson A, Ryden L,. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J 1989; 10: 423-428.
32. O'Connor CM, Gottlieb S, Bourque JM, Krause-Steinrauf H, Anand I, Anderson JL, Plehn JF, Silver MA, White M, Carson P, Investigators B,. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. Am J Cardiol 2005; 95: 558-564.
33. Passmore AP, Whitehead EM, Crawford V, McVeigh GE, Johnston GD,. The antihypertensive and metabolic effects of low and conventional dose cyclopenthiazide in type II diabetics with hypertension. Q J Med 1991; 81: 919-928.
34. Chalon S, Berlin I, Sachon C, Bosquet F, Grimaldi A,. Propranolol in hypoglycaemia unawareness. Diabetes Metab 1999; 25: 23-26.
35. Chellingsworth MC, Kendall MJ, Wright AD, Singh BM, Pasi J,. The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. J Hum Hypertens 1989; 3: 35-39.
36. Klauser R, Prager R, Gaube S, Gisinger C, Schnack C, Küenburg E, Schernthaner G,. Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus. Hypertension 1991; 17: 15-21.
37. Pacy PJ, Dodson PM, Kubicki AJ,. Comparison of the hypotensive and metabolic effects of bendrofluazide therapy and a high fibre, low fat, low sodium diet in diabetic subjects with mild hypertension. J Hypertens 1984; 2: 215-220.
38. Kuo SW, Pei D, Hung YJ, Hsieh AT, Wu LY, Hsieh CH, He CT, Yang TC, Lian WC,. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens 2003; 16: 623-628.
39. Luna B, Feinglos MN,. Drug-induced hyperglycemia. JAMA 2001; 286: 1945-1948.
40. Wai B, Kearney LG, Hare DL, Ord M, Burrell LM, Srivastava PM,. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol 2012; 11: 14.
41. Sarafidis PA, Bakris GL,. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM 2006; 99: 431-436.
42. Ferner RE,. Drug-induced diabetes. Baillières Clin Endocrinol Metab 1992; 6: 849-866.
43. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR,. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
44. Hirst JA, Stevens RJ, Farmer AJ,. Changes in HbA1c level over a 12-week follow-up in patients with type 2 diabetes following a medication change. PLoS ONE 2014; 9: e92458.
45. Whitcroft IA, Thomas JM, Rawsthorne A, Wilkinson N, Thompson H,. Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics. Horm Metab Res Suppl 1990; 22: 42-46.
46. Hunter SJ, Wiggam MI, Ennis CN, Whitehead HM, Sheridan B, Atkinson AB, Bell PM,. Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study. Diabet Med 1999; 16: 482-487.
47. Lewis HM, Kendall MJ, Wright AD, Bratty JR, Maxwell S,. A comparison of the metabolic effects of flosequinan and propranolol in patients with non-insulin-dependent diabetes mellitus. J Clin Pharm Ther 1991; 16: 161-166.
48. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J,. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005; 149: 159-167.
49. Profozic V, Coce F, Babic D, Metelko Z, Rao BA, Schinzer S, Reuter M,. Metabolic effects of ramipril in non-insulin dependent diabetics with essential hypertension. Diabetol Croat 1997; 26: 135-144.
50. de Boer RA, Doehner W, van der Horst ICC, Anker SD, Babalis D, Roughton M, Coats AJ, Flather MD, van Veldhuisen DJ,; SENIORS Investigators. Influence of diabetes mellitus and hyperglycemia on prognosis in patients ≥70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure [SENIORS]). Am J Cardiol 2010; 106: 78-86.e1.
51. Gundersen T, Kjekshus J,. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983; 6: 285-290.
52. Rodda BE,. The Timolol Myocardial Infarction Study: an evaluation of selected variables. Circulation 1983; 67 (6 Pt 2): I101-106.
53. Larijani B, Afshari M, Astanehi-Ashgari F, Mojtahedi A, Rezaie A, Hosseinnezhad A, Heshman R, Mohammadirad A, Abdollahi M,. Effect of short-term carvedilol therapy on salivary and plasma oxidative stress parameters and plasma glucose level in type II diabetes. Therapy 2006; 3: 119-123.
54. Davies JI, Band M, Morris A, Struthers AD,. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004; 47: 1687-1694.
55. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH,. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112.
56. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH,. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542.
57. Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD,. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 2008; 51: 762-768.
58. McLaughlin DM, Atkinson AB, Ennis CN, Browne J, Hunter SJ, Sheridan B, Bell PM,. Comparison of effects of combined ACE inhibitor and low-dose thiazide diuretic with ACE inhibitor alone on insulin action in patients with hypertension and Type 2 diabetes: a double-blind crossover study. Diabet Med 2008; 25: 631-634.